Rare KIT (CD117) Expression in Multiple Myeloma Abrogates the Usefulness of Imatinib Mesylate Treatment

Virchows Archiv - Germany
doi 10.1007/s00428-003-0934-8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Nature

Related search

Development of Multiple Myeloma in a Patient With Chronic Myeloid Leukemia After Treatment With Imatinib Mesylate

Oncologist
Cancer ResearchMedicineOncology
2005English

Overexpression of the KIT/SCF in Uveal Melanoma Does Not Translate Into Clinical Efficacy of Imatinib Mesylate

Clinical Cancer Research
Cancer ResearchOncology
2009English

Expression of Androgen Receptor and C-Kit (CD117) in Triple Negative Breast Cancer

Immunopathology, Allergology, Infectology
2016English

Expression of CD81 and CD117 in Plasma Cell Myeloma and the Relationship to Prognosis

Cancer Medicine
Cancer ResearchNuclear MedicineRadiologyImagingOncology
2018English

Multiple Myeloma Treatment in the Elderly

International Journal of Hematologic Oncology
OncologyHematologyPharmacology
2013English

Ixazomib in the Treatment of Relapsed Multiple Myeloma

Medical Council
2018English

Update on the Treatment of Multiple Myeloma

Oncologist
Cancer ResearchMedicineOncology
2001English

Imatinib Mesylate Causes Growth Plate Closure in Vivo

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2009English

Progress in the Front-Line Treatment of Multiple Myeloma

European Oncology and Haematology
OncologyHematology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy